These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 26500340)

  • 21. Anti-CD20 Antibody with Multimerized Fc Domains: A Novel Strategy To Deplete B Cells and Augment Treatment of Autoimmune Disease.
    Zhang X; Olsen HS; Chen S; So E; Zhou H; Burch E; Mérigeon EY; Block DS; Strome SE
    J Immunol; 2016 Feb; 196(3):1165-76. PubMed ID: 26695368
    [TBL] [Abstract][Full Text] [Related]  

  • 22. An Engineered Human Fc variant With Exquisite Selectivity for FcγRIIIa
    Kang TH; Lee CH; Delidakis G; Jung J; Richard-Le Goff O; Lee J; Kim JE; Charab W; Bruhns P; Georgiou G
    Front Immunol; 2019; 10():562. PubMed ID: 30984171
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Asymmetrical Fc engineering greatly enhances antibody-dependent cellular cytotoxicity (ADCC) effector function and stability of the modified antibodies.
    Liu Z; Gunasekaran K; Wang W; Razinkov V; Sekirov L; Leng E; Sweet H; Foltz I; Howard M; Rousseau AM; Kozlosky C; Fanslow W; Yan W
    J Biol Chem; 2014 Feb; 289(6):3571-90. PubMed ID: 24311787
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Human cytomegalovirus Fcγ binding proteins gp34 and gp68 antagonize Fcγ receptors I, II and III.
    Corrales-Aguilar E; Trilling M; Hunold K; Fiedler M; Le VT; Reinhard H; Ehrhardt K; Mercé-Maldonado E; Aliyev E; Zimmermann A; Johnson DC; Hengel H
    PLoS Pathog; 2014 May; 10(5):e1004131. PubMed ID: 24830376
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Fc Binding by FcγRIIa Is Essential for Cellular Activation by the Anti-FcγRIIa mAbs 8.26 and 8.2.
    Wines BD; Trist HM; Esparon S; Impey RE; Mackay GA; Andrews RK; Soares da Costa TP; Pietersz GA; Baker RI; Hogarth PM
    Front Immunol; 2021; 12():666813. PubMed ID: 34759915
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Protease-Activation of Fc-Masked Therapeutic Antibodies to Alleviate Off-Tumor Cytotoxicity.
    Elter A; Yanakieva D; Fiebig D; Hallstein K; Becker S; Betz U; Kolmar H
    Front Immunol; 2021; 12():715719. PubMed ID: 34413859
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Multi-Angle Effector Function Analysis of Human Monoclonal IgG Glycovariants.
    Dashivets T; Thomann M; Rueger P; Knaupp A; Buchner J; Schlothauer T
    PLoS One; 2015; 10(12):e0143520. PubMed ID: 26657484
    [TBL] [Abstract][Full Text] [Related]  

  • 28. An engineered Fc variant of an IgG eliminates all immune effector functions via structural perturbations.
    Vafa O; Gilliland GL; Brezski RJ; Strake B; Wilkinson T; Lacy ER; Scallon B; Teplyakov A; Malia TJ; Strohl WR
    Methods; 2014 Jan; 65(1):114-26. PubMed ID: 23872058
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mechanisms of action of intravenous immunoglobulin in the treatment of immune thrombocytopenia.
    Crow AR; Song S; Siragam V; Lazarus AH
    Pediatr Blood Cancer; 2006 Oct; 47(5 Suppl):710-3. PubMed ID: 16933274
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Role of Malt1 protease activity in pathogenesis of inflammatory disorders mediated by FcγR signaling.
    Nakamura Y; Yokoyama K; Igaki K; Tsuchimori N
    Int Immunopharmacol; 2018 Mar; 56():193-196. PubMed ID: 29414650
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Thrombopoietin receptor agonists shift the balance of Fcγ receptors toward inhibitory receptor IIb on monocytes in ITP.
    Liu XG; Liu S; Feng Q; Liu XN; Li GS; Sheng Z; Chen P; Liu Y; Wei Y; Dong XY; Qin P; Gao C; Ma C; Zhang L; Hou M; Peng J
    Blood; 2016 Aug; 128(6):852-61. PubMed ID: 27281793
    [TBL] [Abstract][Full Text] [Related]  

  • 32. IgG Fc variant cross-reactivity between human and rhesus macaque FcγRs.
    Boesch AW; Miles AR; Chan YN; Osei-Owusu NY; Ackerman ME
    MAbs; 2017 Apr; 9(3):455-465. PubMed ID: 28055295
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CD44 Antibody Inhibition of Macrophage Phagocytosis Targets Fcγ Receptor- and Complement Receptor 3-Dependent Mechanisms.
    Amash A; Wang L; Wang Y; Bhakta V; Fairn GD; Hou M; Peng J; Sheffield WP; Lazarus AH
    J Immunol; 2016 Apr; 196(8):3331-40. PubMed ID: 26944929
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Modulating immunogenicity of factor IX by fusion to an immunoglobulin Fc domain: a study using a hemophilia B mouse model.
    Levin D; Lagassé HA; Burch E; Strome S; Tan S; Jiang H; Sauna ZE; Golding B
    J Thromb Haemost; 2017 Apr; 15(4):721-734. PubMed ID: 28166609
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Requirement of Mucosa-Associated Lymphoid Tissue Lymphoma Translocation Protein 1 Protease Activity for Fcγ Receptor-Induced Arthritis, but Not Fcγ Receptor-Mediated Platelet Elimination, in Mice.
    Martin K; Touil R; Cvijetic G; Israel L; Kolb Y; Sarret S; Valeaux S; Degl'Innocenti E; Le Meur T; Caesar N; Bardet M; Beerli C; Zerwes HG; Kovarik J; Beltz K; Schlapbach A; Quancard J; Régnier CH; Bigaud M; Junt T; Wieczorek G; Isnardi I; Littlewood-Evans A; Bornancin F; Calzascia T
    Arthritis Rheumatol; 2020 Jun; 72(6):919-930. PubMed ID: 31943941
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Simultaneous exposure to FcγR and FcαR on monocytes and macrophages enhances antitumor activity in vivo.
    Li B; Xu L; Tao F; Xie K; Wu Z; Li Y; Li J; Chen K; Pi C; Mendelsohn A; Larrick JW; Gu H; Fang J
    Oncotarget; 2017 Jun; 8(24):39356-39366. PubMed ID: 28454118
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Fc-Fusion Drugs Have FcγR/C1q Binding and Signaling Properties That May Affect Their Immunogenicity.
    Lagassé HAD; Hengel H; Golding B; Sauna ZE
    AAPS J; 2019 May; 21(4):62. PubMed ID: 31062128
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A novel monoclonal antibody with improved FcγR blocking ability demonstrated non-inferior efficacy compared to IVIG in cynomolgus monkey ITP model at considerably lower dose.
    Nakajima-Kato Y; Komai M; Yoshida T; Kanai A
    Clin Exp Immunol; 2023 Mar; 211(1):23-30. PubMed ID: 36480334
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Plasmacytoid dendritic cells, interferon signaling, and FcγR contribute to pathogenesis and therapeutic response in childhood immune thrombocytopenia.
    Sehgal K; Guo X; Koduru S; Shah A; Lin A; Yan X; Dhodapkar KM
    Sci Transl Med; 2013 Jul; 5(193):193ra89. PubMed ID: 23843450
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Rapid desensitization of mice with anti-FcγRIIb/FcγRIII mAb safely prevents IgG-mediated anaphylaxis.
    Khodoun MV; Kucuk ZY; Strait RT; Krishnamurthy D; Janek K; Clay CD; Morris SC; Finkelman FD
    J Allergy Clin Immunol; 2013 Dec; 132(6):1375-87. PubMed ID: 24139828
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.